New pill-chemo combo takes on hard-to-treat cancers
NCT ID NCT07667400
First seen Jun 26, 2026 · Last updated Jul 01, 2026 · Updated 4 times
Summary
This study tests a new drug called SX-682 (a tablet) combined with the chemotherapy docetaxel in people whose head/neck, salivary gland, or prostate cancer has spread or returned after treatment. The goal is to find the right dose and see if the combination shrinks tumors. About 120 adults will take part, receiving the drugs in 3-week cycles for up to 6 cycles.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
SX-682 (a tablet) and docetaxel (a chemotherapy drug given by IV)
What this could lead to
If it works, this combination could offer a new treatment option for people with head/neck or prostate cancers that have spread or come back.
What could go wrong
This is an early-phase trial (Phase I/II) with only 120 participants, so it may not show enough benefit or could have side effects. The drugs may not work for all cancer types studied.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADENOID CYSTIC CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••